Effect of "Cydonia Oblonga" fruit on nausea and vomiting in pregnancy

Comparison of "Cydonia Oblonga" fruit product with B6 on nausea and vomiting in pregnancy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012081110559N1

Enrollment

Registered

2013-03-03

Start date

2013-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea and vomiting induced by pregnancy. Vomiting of pregnancy, unspecified

Interventions

Intervention 1: Intervention: syrup of Quince fruit, 1 table spoon three times a day before meals for one week Control: Vitamin B-6 20 mg tablet three times daily before meals for one week. Interv

Treatment - Drugs

Intervention: syrup of Quince fruit, 1 table spoon three times a day before meals for one week Control: Vitamin B-6 20 mg tablet three times daily before meals for one week

control: Vitamin B-6 20 mg tablet three times daily before meals for one week

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age 18-40 years, gestational age 6-14 weeks, singleton pregnancy with live fetus based on ultrasound, mild to moderate nausea and vomiting of pregnancy (13 > score of PUQE 24 Questionnaire = 6) Exclusion criteria: severe nausea and vomiting during pregnancy that may require fluid therapy and hospitalization, nausea and vomiting of pregnancy by secondary causes: peptic ulcer, hepatitis, pyelonephritis, pancreatitis, cholecystitis, appendicitis, gastroenteritis, UTI, CNS disorders, gasteroesophageal reflux disease, hyperthyroidism, multiple pregnancy, ectopic pregnancy, mole, presence of pregnancy complications such as bleeding, threatened abortion, history of chronic disease, history of drug addiction, alcoholism and smoking, history of drug allergy, and at least 48 hours before presentation anti- nausea medication (B6, Metoclopramide, etc.) are not used

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Nausea. Timepoint: Before, one week and two weeks after intervention. Method of measurement: PUQE 24 hours Questionnaire and VAS (Visual Analogue Scale).;Vomiting. Timepoint: Before, one week and two weeks after intervention. Method of measurement: PUQE 24 hours Questionnaire and VAS (Visual Analogue Scale).;Retching. Timepoint: Before, one week and two weeks after intervention. Method of measurement: PUQE 24 hours questionnaire and VAS (Visual Analogue Scale).	—

Measure

Time frame

Nausea. Timepoint: Before, one week and two weeks after intervention. Method of measurement: PUQE 24 hours Questionnaire and VAS (Visual Analogue Scale).;Vomiting. Timepoint: Before, one week and two weeks after intervention. Method of measurement: PUQE 24 hours Questionnaire and VAS (Visual Analogue Scale).;Retching. Timepoint: Before, one week and two weeks after intervention. Method of measurement: PUQE 24 hours questionnaire and VAS (Visual Analogue Scale).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEfat Jafari Dehkordi

Faculty of Traditional Medicine, Tehran University of Medical Sciences

e-jafarid@razi.tums.ac.ir+98 21 5569 3520

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026